AstraZeneca has paused a 200 million pound sterling ($271 million) investment in its Cambridge, England research site, a ...

Not all cardiac arrests can be treated with an electric shock. In fact, most of them—about 80%—are ineligible for ...

Eli Lilly is reconsidering plans for its U.K. biotech-focused Gateway Labs, citing concerns about the industry’s outlook in ...

Philips and Masimo are renewing their years-long collaboration in patient monitoring, with what they describe as an expanded ...

Like approved Alzheimer’s meds Kisunla (donanemab) and Leqembi (lecanemab), as well as the discontinued Aduhelm (aducanemab), ...

With its head of U.S. business Julie Kim sliding up to the CEO spot next June, Takeda has locked in a replacement in Rhona ...

Protara applies modern science, manufacturing, and regulatory expertise to reimagine proven medicines and deliver new ...

Researchers at Mass General Brigham in Boston have designed a custom gene editing technique that corrected the mutation ...

Exact Sciences has launched its long-awaited blood test designed to detect the early stages of multiple tumors, with a plan ...

Arrowhead Pharmaceuticals has launched legal action against Ionis Pharmaceuticals, aiming to neutralize Ionis' claim that ...

FibroGen has agreed to pay $1.25 million to the Securities and Exchange Commission (SEC) to address allegations that the ...

Capsida Biotherapeutics has paused a gene therapy trial after the first patient died. | Capsida Biotherapeutics has paused a ...